$3250 | Single User
$6500 | Site License
$9750 | Enterprise License

Metastatic Hepatocellular Carcinoma - Epidemiology Forecast to 2027
[Report Updated: 14-02-2018]

Published by Delve Insight: 14 Feb 2018 | 201490 | In Stock

Introduction

DelveInsight's "Metastatic Hepatocellular Carcinoma - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Metastatic Hepatocellular Carcinoma epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

Markets Covered

• United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2016-2027

Metastatic Hepatocellular Carcinoma Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Metastatic Hepatocellular Carcinoma in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Metastatic Hepatocellular Carcinoma outlook. It also includes the explanation of changing trends of epidemiology outlining the Metastatic Hepatocellular Carcinoma scenario.

Metastatic Hepatocellular Carcinoma Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Metastatic Hepatocellular Carcinoma thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

• The report covers detailed overview of Metastatic Hepatocellular Carcinoma explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

• The Metastatic Hepatocellular Carcinoma Report assesses the disease risk and burden and highlights the unmet needs

• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

• 10 Year Forecast

• 7MM Coverage

• Total Cases in Metastatic Hepatocellular Carcinoma

Key assessments

• Patient Segmentation in Metastatic Hepatocellular Carcinoma

• Metastatic Hepatocellular Carcinoma Risk & Burden

• Factors driving growth in a specific Metastatic Hepatocellular Carcinoma patient population

Table of Contents
for Metastatic Hepatocellular Carcinoma - Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

  • 1. Report Introduction

    2. Metastatic Hepatocellular Carcinoma Epidemiology Overview at a Glance

    2.1. Patient Share Distribution of Metastatic Hepatocellular Carcinoma in 2017

    2.2. Patient Share Distribution of Metastatic Hepatocellular Carcinoma in 2027

    3. Disease Background and Overview: Metastatic Hepatocellular Carcinoma

    3.1. Introduction

    3.2. Symptoms

    3.3. Etiology

    3.4. Risk Factors

    3.5. Pathophysiology

    3.6. Diagnosis

    3.7. Treatment

    4. Epidemiology and Patient Population

    4.1. Key Findings

    4.2. Total Prevalent/ Incident Patient Population of Metastatic Hepatocellular Carcinoma in 7MM

    4.3. Total Prevalent/ Incident Patient Population of Metastatic Hepatocellular Carcinoma in 7MM – By Countries

    5. Epidemiology of Metastatic Hepatocellular Carcinoma by Countries

    5.1. United States

    5.1.1. Assumptions and Rationale

    5.1.2. Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma

    5.1.3. Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma *

    5.1.4. Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma *

    5.1.5. Diagnosed Cases of the Metastatic Hepatocellular Carcinoma

    5.2. EU5

    5.3. Assumptions and Rationale

    5.4. Germany

    5.4.1. Assumptions and Rationale

    5.4.2. Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma

    5.4.3. Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma *

    5.4.4. Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma *

    5.4.5. Diagnosed Cases of the Metastatic Hepatocellular Carcinoma

    5.5. France

    5.5.1. Assumptions and Rationale

    5.5.2. Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma

    5.5.3. Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma *

    5.5.4. Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma *

    5.5.5. Diagnosed Cases of the Metastatic Hepatocellular Carcinoma

    5.6. Italy

    5.6.1. Assumptions and Rationale

    5.6.2. Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma

    5.6.3. Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma *

    5.6.4. Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma *

    5.6.5. Diagnosed Cases of the Metastatic Hepatocellular Carcinoma

    5.7. Spain

    5.7.1. Assumptions and Rationale

    5.7.2. Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma

    5.7.3. Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma *

    5.7.4. Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma *

    5.7.5. Diagnosed Cases of the Metastatic Hepatocellular Carcinoma

    5.8. United Kingdom

    5.8.1. Assumptions and Rationale

    5.8.2. Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma

    5.8.3. Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma *

    5.8.4. Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma *

    5.8.5. Diagnosed Cases of the Metastatic Hepatocellular Carcinoma

    5.9. Japan

    5.9.1. Assumptions and Rationale

    5.9.2. Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma

    5.9.3. Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma *

    5.9.4. Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma *

    5.9.5. Diagnosed Cases of the Metastatic Hepatocellular Carcinoma

    6. Unmet Needs of the Metastatic Hepatocellular Carcinoma

    7. Appendix

    8. Report Methodology

    8.1. Sources

    9. DelveInsight Capabilities

    10. Disclaimer

    11. About DelveInsight

    *Indication Specific

List Of Tables
in Metastatic Hepatocellular Carcinoma - Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

Table 1: Total Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma in 7MM

Table 2: Total Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma in United States (2016-2027)*

Table 5: Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma in United States (2016-2027)*

Table 6: Diagnosed Cases of the Metastatic Hepatocellular Carcinoma in United States (2016-2027)

Table 7: Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma in Germany (2016-2027)

Table 8: Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma in Germany (2016-2027) *

Table 9: Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma in Germany (2016-2027) *

Table 10: Diagnosed Cases of the Metastatic Hepatocellular Carcinoma in Germany (2016-2027)

Table 11: Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma in France (2016-2027)

Table 12: Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma in France (2016-2027) *

Table 13: Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma in France (2016-2027) *

Table 14: Diagnosed Cases of the Metastatic Hepatocellular Carcinoma in France (2016-2027)

Table 15: Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma in Italy (2016-2027)

Table 16: Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma in Italy (2016-2027) *

Table 17: Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma in Italy (2016-2027) *

Table 18: Diagnosed Cases of the Metastatic Hepatocellular Carcinoma in Italy (2016-2027)

Table 19: Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma in Spain (2016-2027)

Table 20: Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma in Spain (2016-2027) *

Table 21: Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma in Spain (2016-2027) *

Table 22: Diagnosed Cases of the Metastatic Hepatocellular Carcinoma in Spain (2016-2027)

Table 23: Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma in UK (2016-2027)

Table 24: Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma in UK (2016-2027) *

Table 25: Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma in UK (2016-2027) *

Table 26: Diagnosed Cases of the Metastatic Hepatocellular Carcinoma in UK (2016-2027)

Table 27: Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma in Japan (2016-2027)

Table 28: Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma in Japan (2016-2027) *

Table 29: Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma in Japan (2016-2027) *

Table 30: Diagnosed Cases of the Metastatic Hepatocellular Carcinoma in Japan (2016-2027)

List Of Figures, Charts and Diagrams
in Metastatic Hepatocellular Carcinoma - Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

Table 1: Total Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma in 7MM

Table 2: Total Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma in United States (2016-2027)*

Table 5: Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma in United States (2016-2027)*

Table 6: Diagnosed Cases of the Metastatic Hepatocellular Carcinoma in United States (2016-2027)

Table 7: Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma in Germany (2016-2027)

Table 8: Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma in Germany (2016-2027) *

Table 9: Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma in Germany (2016-2027) *

Table 10: Diagnosed Cases of the Metastatic Hepatocellular Carcinoma in Germany (2016-2027)

Table 11: Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma in France (2016-2027)

Table 12: Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma in France (2016-2027) *

Table 13: Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma in France (2016-2027) *

Table 14: Diagnosed Cases of the Metastatic Hepatocellular Carcinoma in France (2016-2027)

Table 15: Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma in Italy (2016-2027)

Table 16: Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma in Italy (2016-2027) *

Table 17: Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma in Italy (2016-2027) *

Table 18: Diagnosed Cases of the Metastatic Hepatocellular Carcinoma in Italy (2016-2027)

Table 19: Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma in Spain (2016-2027)

Table 20: Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma in Spain (2016-2027) *

Table 21: Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma in Spain (2016-2027) *

Table 22: Diagnosed Cases of the Metastatic Hepatocellular Carcinoma in Spain (2016-2027)

Table 23: Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma in UK (2016-2027)

Table 24: Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma in UK (2016-2027) *

Table 25: Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma in UK (2016-2027) *

Table 26: Diagnosed Cases of the Metastatic Hepatocellular Carcinoma in UK (2016-2027)

Table 27: Prevalent/Incident Cases of the Metastatic Hepatocellular Carcinoma in Japan (2016-2027)

Table 28: Sub-Type Specific cases of the Metastatic Hepatocellular Carcinoma in Japan (2016-2027) *

Table 29: Sex- Specific Cases of the Metastatic Hepatocellular Carcinoma in Japan (2016-2027) *

Table 30: Diagnosed Cases of the Metastatic Hepatocellular Carcinoma in Japan (2016-2027)

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

201490 | DIEI0140

Number of Pages

50

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016
Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016SummaryGlobalData's...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,500 More Info
Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?
Scope Two recent developments appear poised to shift the typical US-based treatment regimen for firs...
13 Jul 2014 by FirstWord Pharma USD $695 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

Metastatic Hepatocellular Carcinoma - Epidemiology Forecast to 2027 [Report Updated: 14-02-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...